AstraZeneca’s Lynparza Adds Narrow Prostate Cancer Indication
FDA Follows Advisory Panel Recommendation On PARP Inhibitor
Executive Summary
AstraZeneca had hoped data from Phase III PROpel would lead to an all-comers indication in first-line, metastatic castration-resistant prostate cancer, but new indication is limited to BRCA mutations.
You may also be interested in...
Akeega Approval Means Three-Way PARP/Anti-Androgen Race In Prostate Cancer Is On
Despite the advantage of a single pill, the J&J drug could have the potential disadvantage of a narrower label in both the US and EU and Lynparza/Zytiga’s potentially higher efficacy.
Pfizer Scores Broad Label For Talzenna/Xtandi In Valuable First-Line Prostate Cancer Indication
The FDA approved the combination for patients with HRR gene-mutated disease, giving it a broader label than the BRCA-mutation label that AstraZeneca/Merck got for Lynparza/Zytiga.
Biomarker-Restricted Indication Urged For AstraZeneca’s Lynparza In First-Line Prostate Cancer
Eleven of 13 members of the Oncologic Drugs Advisory Committee favor limiting olaparib’s use with abiraterone in metastatic castration-resistant prostate cancer to patients with tumors that carry the BRCA mutation, a subgroup that represented only 11% of the patients in the PROpel study.